CORONA
23.7.2024 09:42:34 CEST | Business Wire | Press release
Today, Corona Cero, the global beer sponsor of the Olympic & Paralympic Games, unveils its Golden Venues activation, bringing the same seats as from the Olympic Games venues in Paris to iconic travel destinations across four continents. This initiative invites fans to reconnect with nature and gives them the opportunity to embrace their own Golden Moments every day as part of Corona Cero’s ‘For Every Golden Moment’ platform. This activation uses the same seats as from some of the Olympic Games venues in Paris, like Champ de Mars, Grand Palais, and Le Concorde and placed them in iconic travel destinations worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722637366/en/
Greece - Corona Cero Golden Venues activation (Photo: Corona Cero)
The brand is featuring Golden Venues in 11 breath-taking outdoor settings across 9 countries, including renowned spots such as Arpoador beach in Rio de Janeiro, Brazil, the Grand Peninsula Lagonissi in Athens, Greece, and Café Del Mar in Cartagena, Colombia, offering panoramic views of their respective landscapes. The locations were selected for their remarkable sunsets, scenic beauty and cultural significance, offering visitors a unique opportunity to enjoy a touch of the Olympics amidst spectacular natural settings.
“From Greece, Brazil, Japan, South Africa and Argentina, Corona Cero is offering this gift to fans as an opportunity to experience the Olympic golden moment feeling through Golden Venues,” said Clarissa Pantoja, Vice President of Corona Global. “By bringing the same seats as from Olympic Games stadiums used throughout Paris to these incredible locations worldwide, we are reminding fans that golden moments not only exist within the Olympic Games, but also in the beauty of nature that’s around all of us.”
Corona, recognized as the world’s most valuable beer brand in Kantar’s BrandZ global 2024 rankings, has a rich history of promoting outdoor experiences and encouraging environmental stewardship. The brand is committed to fostering connections and creating meaningful moments in locations that resonate with fans globally.
The full list of Golden Venues spans:
Europe
- Grand Peninsula Lagonissi in Athens, Greece, a popular beach and sailing destination on the Athenian Riviera with panoramic views of the Saronic Gulf;
- Thames Riverfront in Battersea, London, UK, a bustling district with local and tourist attractions, including a riverside promenade, ecological areas, and sports facilities;
South America
- Arpoador Beach in Rio de Janeiro, Brazil, next to Ipanema beach, this landmark destination is renowned for surfing and the best sunset views in town;
- Café Del Mar in Cartagena, Colombia, located 150m high at the top of Old Town, Cafe Del Mar offers 360-views of Cartagena and is known for its stunning sunsets;
- Coatepeque Volcano, El Salvador, a volcanic crater located 745 meters above sea level overlooking a 50,000 years old lake;
- San Carlos de Bariloche, Argentina, a popular ski destination in the Argentinean Patagonia, surrounded by scenic forests and mountains;
- Pichilemu in Punta de Lobos, Chile, a distinct beach with gray sand and large cliffs, Pichilemu is the heart of surf culture in Chile where many of the country's best surfers learned their skills;
Asia
- Morito Beach in Kanagawa, Japan, known for its stunning views of Mt. Fuji, Morito Beach is one of the most famous spots on the coast of the Miura Peninsula;
Africa
- South Africa (three locations) including Cape Town’s Signal Hill, offering panoramic views of V&A Waterfront, the Atlantic Ocean, Lion’s Head, and the iconic Table Mountain, one of the world's Seven Wonders of Nature.
“As the world anticipates the start of the Olympics, we are proud to see Corona Cero bring a touch of the Games to these global iconic locations for more fans to connect to their golden moments,” said Anne-Sophie Voumard, Managing Director IOC Television & Marketing Services. “We hope this gift will inspire people to embrace their own celebratory moments everyday!”
Fans can take in the beauty of nature while celebrating life’s golden moments – together with a refreshing Corona Cero served with a lime, or in any way they prefer to unwind and reconnect with nature. In select locations, the brand is also offering Sunset Hours, which are free concerts by local bands near the Golden Venues locations.
As the first-ever global beer sponsor of the Olympic Games, the no-alcohol beer brand is also elevating the role of moderation in Olympic celebrations globally, creating spaces and moments for cheers and choice in meaningful locations that matter to fans.
AB InBev brands have seen countless new friendships, connections, and experiences built on a shared love of sport and are pleased to be a part of that legacy with decades of historic, award-winning and responsible sports marketing.
The Golden Venues will be open to the public daily during the Olympic Games, starting July 23 with plans to remain in the area after the games.
###
About Corona Global
Corona, an AB InBev global brand*, is the iconic beer brand that is synonymous with paradise with a presence in 180 countries. Recognized as the world’s most valuable beer brand in Kantar’s BrandZ global 2024 rankings, Corona invites the world outside, beckoning you to reconnect with your essential nature and embrace the simple pleasures of life. But it's not just about the beer – it's about the ritual. The ritual of adding a slice of lime to your Corona, an experience that elevates the moment. Corona isn't just a beverage; it's nature in a bottle. And we strive to help protect nature and have become the first global beverage brand with a net-zero plastic footprint. This builds on our longstanding ambition to help protect the world’s oceans and beaches from plastic pollution. Every sip of Corona is a celebration of nature and the beauty of the world around us.
*Corona is not sold by AB InBev in the United States.
About The International Olympic Committee
The International Olympic Committee is a not-for-profit independent international organisation made up of volunteers, which is committed to building a better world through sport. It redistributes more than 90 per cent of its income to the wider sporting movement, which means that every day the equivalent of USD 4.25 million goes to help athletes and sports organisations at all levels around the world.
About AB InBev
AB InBev is a publicly traded company (Euronext: ABI) based in Leuven, Belgium, with secondary listings on the Mexico (MEXBOL: ANB) and South Africa (JSE: ANH) stock exchanges and with American Depositary Receipts on the New York Stock Exchange (NYSE: BUD). As a company, we dream big to create a future with more cheers. We are always looking to serve up new ways to meet life’s moments, move our industry forward and make a meaningful impact in the world. We are committed to building great brands that stand the test of time and to brewing the best beers using the finest ingredients. Our diverse portfolio of well over 500 beer brands includes global brands Budweiser®, Corona®, Stella Artois® and Michelob Ultra®; multi-country brands Beck’s®, Hoegaarden® and Leffe®; and local champions such as Aguila®, Antarctica®, Bud Light®, Brahma®, Cass®, Castle®, Castle Lite®, Cristal®, Harbin®, Jupiler®, Modelo Especial®, Quilmes®, Victoria®, Sedrin®, and Skol®. Our brewing heritage dates back more than 600 years, spanning continents and generations. From our European roots at the Den Hoorn brewery in Leuven, Belgium. To the pioneering spirit of the Anheuser & Co brewery in St. Louis, US. To the creation of the Castle Brewery in South Africa during the Johannesburg gold rush. To Bohemia, the first brewery in Brazil. Geographically diversified with a balanced exposure to developed and developing markets, we leverage the collective strengths of approximately 155,000 colleagues based in nearly 50 countries worldwide. For 2023, AB InBev’s reported revenue was 59.4 billion USD (excluding JVs and associates).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240722637366/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
